pcn poster

Posters

Patient Preferences Concerning the Efficacy and Side Effect Profile of Schizophrenia Medication: A Survey of Patients Living With Schizophrenia

This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida. Background: A survey was carried out to investigate the relative importance of an...

Eric Achtyes , MD;

Anna Skabeev , MD;

Ying Jiang , PhD;

Peter J. Weiden , MD, PhD;

Patricia Marcy , BSN;

Nikki Levy , BS ;

Adam Simmons , MPH;

03/01/2019

Paroxetine, but Not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults

This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida. Sexual dysfunction may be associated with major depressive disorder (MDD) or with...

Paula Jacobsen , PhD;

Wei Zhong , PhD;

George Nomikos , PhD;

Anita H. Clayton , MD;

03/01/2019

This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida. Background: There is limited literature on treatment patterns, healthcare resourc...

Charmi Patel , BS , RN, BSN, MPH;

Antoine C. El Khoury , PhD;

Ahong Huang , BS , MS;

Kruti Joshi , MPH, MD;

Li Wang , MS, MBA, PhD, MA;

Onur Baser , PhD, ScM, BS , MS;

03/01/2019

Non-Medical Use of Prescription Stimulants Reported by Adults Entering Substance Abuse Treatment

This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida.

Jody Green , PhD;

Natasha Oyedele , MPH, MSc;

Stephen Butler , PhD;

Stephen V. Faraone , PhD;

Jeffrey Newcorn , MD;

03/01/2019

Personalized Goal Attainment After a Switch to Vortioxetine in a Phase 4 Open-Label Trial in Adults With Major Depressive Disorder (MDD): Health Outcomes and Progress Toward Functional Recovery

This poster was presented at the 30th annual Psych Congress, held Sept. 16-19, 2017, in New Orleans, Louisiana. Traditional measures of MDD treatment response may miss meaningful change...

03/01/2019

Personalized Goal Attainment After a Switch to Vortioxetine in Adults With Major Depressive Disorder (MDD): Results of a Phase 4 Open-Label Clinical Trial

This Phase 4 open-label trial evaluated real-world effectiveness of the antidepressant vortioxetine on the ability of patients with MDD to achieve pre-identified treatment goals.

Anna Eramo , MD;

Sagar Parikh , MD;

Lisa Mucha , PhD;

Clement Francois , PhD;

Sara Sarkey , PhD;

03/01/2019

Perspectives and Experiences of Individuals Living With Depression: Severity of Condition, Wellbeing, and Quality of Life

Background: Most people with depression do not achieve adequate treatment response. People’s perceptions of their depression and treatment outcomes are crucial to understanding challenges...

Andrew Nierenberg , MD, MGH;

Julia Carpenter-Conlin , MSW;

Amy O'Sullivan , PhD;

Halli Benson , MPH;

Anju Parthan , PhD;

Craig Krebsbach , MA, MS;

Phyllis Foxworth , BS;

Nikki Levy , BS ;

03/01/2019

Pharmacodynamics and Tolerability of Intranasally Administered Immediate Release Amphetamine Sulfate Among Recreational Intranasal Stimulant Users

Introduction: Despite increased nonmedical use of ADHD prescription stimulants, there are limited data to inform selection of intranasal doses for abuse-potential evaluations. This study ...

03/01/2019

Neurobiology of Treatment-Resistant Schizophrenia

Treatment-resistant schizophrenia (TRS) occurs in up to 30% of patients with schizophrenia and is defined as the persistence of positive symptoms despite ≥2 trials of antipsychotic (AP) m...

John Kane , MD;

Steven Potkin , MD;

Jean-Pierre Lindenmayer , MD;

Ofer Agid , MD;

Christoph U. Correll , MD;

Stephen Marder , MD;

Oliver Howes , MD;

03/01/2019

Modeling the Natural Course of Treatment-Resistant Depression Using the US STAR*D Data

Predictive equations were derived to characterize the natural course of treatment-resistant depression (TRD). Patients experiencing major depressive disorder symptoms after failing two an...

Qiaoyi Zhang , MD, PhD;

Hoa Le , PhD;

Hector Toro-Diaz , PhD;

Shujun Li , MS;

Luis Hernandez , MSc;

Shien Guo , PhD;

Arman Altincatal , MS;

Josh Weng , MS;

03/01/2019

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products